Mann, CEO of Asp Isotopes, sells $1.37m in ASPI stock

Published 11/09/2025, 02:06
Mann, CEO of Asp Isotopes, sells $1.37m in ASPI stock

Paul Elliot Mann, Chief Executive Officer and a director at ASP Isotopes Inc (NASDAQ:ASPI), sold 162,153 shares of common stock on September 8 and 9, 2025, for approximately $1.37 million. The sales occurred at prices ranging from $8.3886 to $8.5279. The transaction comes as ASPI shares have delivered a remarkable 232% return over the past year, according to InvestingPro data.

According to a Form 4 filing with the Securities and Exchange Commission, the transactions were executed to cover tax withholding obligations related to the vesting of restricted stock awards, pursuant to a pre-arranged Rule 10b5-1 trading plan.

On September 9, Mann also exercised options to acquire 1,216,000 shares of ASP Isotopes common stock at a price of $2.00 per share, for a total value of $2,432,000.

Additionally, the company withheld 285,110 shares for $2,431,988 to cover the exercise price associated with the stock options.

Following these transactions, Mann directly owns 8,084,191 shares of ASP Isotopes Inc.

In other recent news, ASP Isotopes Inc. has made several strategic moves. The company announced a Memorandum of Understanding with Fermi America to explore developing a High Assay Low Enriched Uranium (HALEU) enrichment facility in Texas. This facility aims to bolster domestic supply chains for nuclear fuel. ASP Isotopes also formed a joint venture with Fermi America and its subsidiary Quantum Leap Energy LLC to advance the production of HALEU for small modular reactors. Additionally, ASP Isotopes has invested $5 million in seed funding into IsoBio, Inc., a company focused on developing antibody-isotope conjugates for cancer treatment. On the corporate governance front, Ralph L. Hunter has been appointed to the board of directors of ASP Isotopes and its subsidiary Quantum Leap Energy LLC. Hunter brings over 30 years of experience in the nuclear power industry. These developments reflect ASP Isotopes’ ongoing efforts to expand its capabilities in nuclear technology and materials.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.